News for Lotus Pharmaceuticals, Inc. (LTUS)

Published at

Mar 18, 2025 3:00 PM

by gurufocus.com

mixed

mixed

Alvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as ”Dr. Reddy's”) a

VGID TEVJF TEVA LTUS KMDA.TA KMDA CIPLA.NS CIPLA.BO AMGN.MX AMGN.BA AMGN AMG.DE 4554.T

Read more →
Published at

Mar 18, 2025 1:53 PM

by manilatimes.net

mixed

mixed

Alvotech and Dr. Reddy's Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

**media[569574]**

VGID RDY DRREDDY.NS DRREDDY.BO TEVJF TEVA LTUS KMDA.TA KMDA CIPLA.NS CIPLA.BO AMGN.MX AMGN.BA AMGN AMG.DE 4554.T

Read more →
Published at

Mar 18, 2025 1:53 PM

by manilatimes.net

mixed

mixed

Alvotech and Dr. Reddy's Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

**media[569571,569572]**

VGID RDY DRREDDY.NS DRREDDY.BO TEVJF TEVA LTUS KMDA.TA KMDA CIPLA.NS CIPLA.BO AMGN.MX AMGN.BA AMGN AMG.DE 4554.T

Read more →
Published at

May 21, 2024 4:16 PM

by investing.com

mixed

mixed

Alvotech and Dr. Reddy's Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia ® & Xgeva ® in the U.S., Europe and UK By Investing.com

Alvotech and Dr. Reddy's Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia ® & Xgeva ® in the U.S., Europe and UK

VGID RDY DRREDDY.NS DRREDDY.BO AMGN.MX AMGN.BA AMGN AMG.DE TEVJF TEVA LTUS CIPLA.NS CIPLA.BO 4554.T

Read more →
Published at

Apr 8, 2024 2:40 PM

by investing.com

mixed

mixed

NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression By Investing.com

NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

LTUS NRXP

Read more →
Published at

May 1, 2022 12:20 PM

by etfdailynews.com

positive

positive

Critical Analysis: Lotus Pharmaceuticals (OTCMKTS:LTUS) & AbbVie (NYSE:ABBV)

Read Critical Analysis: Lotus Pharmaceuticals (OTCMKTS:LTUS) & AbbVie (NYSE:ABBV) at ETF Daily News

LTUS ABBV34.SA ABBV.MX ABBV.BA ABBV 4AB.DE

Read more →
Published at

Nov 22, 2021 11:18 PM

by marketscreener.com

positive

positive

Lotus Pharmaceuticals : Informational Disclosure

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines 8551 Lamar Court North Port, FL 34287 ... | November 22, 2021

OTCM LTUS

Read more →
Published at

Nov 22, 2021 11:18 PM

by marketscreener.com

positive

positive

Lotus Pharmaceuticals : Unaudited Financial Statements

FINANCIAL STATEMENTS and Notes to Financial Statements Lotus PharmaceuticaIs, Inc. For the... | November 22, 2021

LTUS

Read more →
Published at

Mar 17, 2021 1:12 PM

by prnewswire.com

positive

positive

Lotus Pharmaceuticals, Inc. Current with OTC MARKETS

/PRNewswire/ -- Lotus Pharmaceuticals, Inc (Pink Sheets: LTUS) President Georgene Rivers announced today that Lotus Pharmaceuticals, Inc. has become current...

OTCM LTUS ABILF

Read more →